We are live on
!
Find out more
KAM
Kazazian Asset Management Portfolio holdings
AUM
$111M
1-Year Est. Return
29.02%
This Fund
S&P 500
This Quarter
Est. Return
+4.85%
1 Year Est. Return
+29.02%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$97.9M
AUM Growth
+$16.2M
(+20%)
Cap. Flow
+$13.7M
Cap. Flow
% of AUM
14.05%
Top 10 Holdings %
Top 10 Hldgs %
51.86%
Holding
86
New
16
Increased
49
Reduced
9
Closed
4
Avg Time Held
4
quarters
Top 10 Avg Time Held
6.9
quarters
Top 20 Avg Time Held
5.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CS
Credit Suisse Group
CS
|
+$1.79M |
| 2 |
NuStar Energy L.P.
NS
|
+$1.64M |
| 3 |
Barclays
BCS
|
+$1.41M |
| 4 |
Global X MLP ETF
MLPA
|
+$988K |
| 5 |
Expedia Group
EXPE
|
+$960K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$408K |
| 2 |
Immunogen Inc
IMGN
|
+$357K |
| 3 |
Chipotle Mexican Grill
CMG
|
+$273K |
| 4 |
Sarepta Therapeutics
SRPT
|
+$265K |
| 5 |
People Inc
PPLI
|
+$249K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.26% |
| 2 | Miscellaneous | 26.81% |
| 3 | Financials | 12.93% |
| 4 | Consumer Discretionary | 11.02% |
| 5 | Communication Services | 6.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
iShares MSCI Emerging Markets ETF
EEM
$31B
| $10.4M | 10.59% |
220,000
+15,000
| +7% | +$694K |
2017 Q2
2 quarters
|
|
2
State Street SPDR S&P 500 ETF Trust
SPY
$822B
| $8.76M | 8.95% |
32,839
+3,255
| +11% | +$846K |
2015 Q1
11 quarters
|
|
3
General Motors
GM
$72.6B
| $7.58M | 7.75% |
184,935
+7,731
| +4% | +$335K |
2014 Q4
12 quarters
|
|
4
DELISTED
DigitalBridge
DBRG
| $5.21M | 5.32% |
114,173
+3,855
| +3% | +$189K |
2017 Q1
3 quarters
|
|
5
Alphabet (Google) Class C
GOOG
$4.25T
| $4.14M | 4.23% |
79,140
+2,500
| +3% | +$127K |
2014 Q4
12 quarters
|
|
6
Citigroup
C
$217B
| $3.86M | 3.94% |
51,815
+1,384
| +3% | +$102K |
2014 Q4
12 quarters
|
|
|
7
Biogen
BIIB
$33.3B
| $2.94M | 3% |
9,229
-1,272
| -12% | -$408K |
2016 Q2
6 quarters
|
|
8
Bausch Health
BHC
$2.26B
| $2.65M | 2.71% |
127,567
+50,256
| +65% | +$797K |
2015 Q4
8 quarters
|
|
|
RESI
9
DELISTED
Front Yard Residential Corporation Common Stock
RESI
| $2.63M | 2.69% |
221,882
+6,957
| +3% | +$77K |
2015 Q3
9 quarters
|
|
10
Apple
AAPL
$4.91T
| $2.61M | 2.67% |
61,684
+1,404
| +2% | +$58.7K |
2014 Q4
12 quarters
|
|
11
iShares Silver Trust
SLV
$29.5B
| $2.2M | 2.25% |
137,746
+5,446
| +4% | +$86K |
2016 Q2
6 quarters
|
|
12
DELISTED
Blueprint Medicines
BPMC
| $2.16M | 2.21% |
28,646
+3,911
| +16% | +$275K |
2017 Q2
2 quarters
|
|
|
ALXN
13
DELISTED
Alexion Pharmaceuticals
ALXN
| $2.07M | 2.11% |
17,283
+6,669
| +63% | +$812K |
2017 Q1
3 quarters
|
|
|
CS
14
DELISTED
Credit Suisse Group
CS
| $1.93M | 1.97% |
+108,000
| New | +$1.79M |
2017 Q4
0 quarters
|
|
15
iShares MSCI Germany ETF
EWG
$1.46B
| $1.89M | 1.93% |
57,093
+2,093
| +4% | +$68.9K |
2017 Q2
2 quarters
|
|
16
Alibaba
BABA
$277B
| $1.56M | 1.59% |
9,031
+328
| +4% | +$58.8K |
2014 Q4
12 quarters
|
|
|
17
Barclays
BCS
$76.6B
| $1.51M | 1.55% |
+145,393
| New | +$1.41M |
2017 Q4
0 quarters
|
|
|
18
DELISTED
NuStar Energy L.P.
NS
| $1.51M | 1.54% |
+50,500
| New | +$1.64M |
2017 Q4
0 quarters
|
|
19
Baidu
BIDU
$29B
| $1.49M | 1.52% |
6,369
+140
| +2% | +$34.2K |
2015 Q3
9 quarters
|
|
|
CLVS
20
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.33M | 1.36% |
19,517
+2,024
| +12% | +$142K |
2017 Q2
2 quarters
|
|
21
Bristol-Myers Squibb
BMY
$121B
| $1.22M | 1.25% |
19,892
-2,452
| -11% | -$153K |
2017 Q1
3 quarters
|
|
22
Nektar Therapeutics
NKTR
$1.41B
| $1.17M | 1.19% |
+1,301
| New | +$770K |
2017 Q4
0 quarters
|
|
|
23
Global X MLP ETF
MLPA
$2.28B
| $1M | 1.02% |
+16,917
| New | +$988K |
2017 Q4
0 quarters
|
|
24
Vertex Pharmaceuticals
VRTX
$129B
| $976K | 1% |
6,512
+675
| +12% | +$99.9K |
2017 Q3
1 quarter
|
|
25
VanEck Gold Miners ETF
GDX
$26.8B
| $967K | 0.99% |
41,596
+715
| +2% | +$16.3K |
2015 Q3
9 quarters
|
|
Similar funds
FF
VR
WCBA
CCM
LA
MASM
PFG
RM
Kazazian Asset Management's Q4 2017 Portfolio in Review
As of Q4 2017, Kazazian Asset Management held 86 positions worth $97.9M, up 20% from $81.7M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Kazazian Asset Management deployed $13.7M of net new capital in Q4 2017, opening 16 new positions and adding to 49 existing holdings. Its largest new stake was Credit Suisse Group: 108,000 shares worth $1.93M.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 27% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Biogen, an estimated $408K trimmed.
- Kazazian Asset Management's largest Q4 2017 buy was Credit Suisse Group: 108,000 shares worth $1.93M.
- Kazazian Asset Management added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $846K increase.
- Kazazian Asset Management's biggest Q4 2017 reduction was Biogen, cutting an estimated $408K.
- Kazazian Asset Management fully exited Immunogen Inc in Q4 2017, selling an estimated $357K.
- Kazazian Asset Management's ten largest holdings make up 52% of its $97.9M portfolio in Q4 2017.
- Kazazian Asset Management opened 16 new positions and closed 4 in Q4 2017.
- Kazazian Asset Management's portfolio value rose 20% quarter-over-quarter to $97.9M.
Based on Kazazian Asset Management's 13F filing for Q4 2017, filed 15 Feb 2018.